Enhanced cellular uptake and metabolic stability of lipo-oligoarginine peptides.

TitleEnhanced cellular uptake and metabolic stability of lipo-oligoarginine peptides.
Publication TypeJournal Article
Year of Publication2011
AuthorsLee JSam, Tung C-H
JournalBiopolymers
Volume96
Issue6
Pagination772-9
Date Published2011
ISSN0006-3525
KeywordsArginine, Chromatography, High Pressure Liquid, Flow Cytometry, Humans, Hydrolysis, Jurkat Cells, Kinetics, Lipids, Peptides, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
Abstract

Developing efficient cellular delivery vectors is crucial for designing novel therapeutic agents to enhance their plasma membrane permeability and metabolic stability in cells. Previously, we engineered cell penetrating peptide vectors named as "lipo-oligoarginine peptides" (LOAPs) by conjugating a proper combination of fatty acid and oligoarginine that translocated into cell easily without adverse effect on cell viability. In the present study, we report a systemic evaluation of cellular uptake and metabolic stability of LOAPs in Jurkat cells by introducing different combination of D-Arg residues in the peptide backbone. The cellular uptake and intracellular fate, cell viability, and metabolic stability and proteolytic degradation patterns of various LOAPs consisted of different combination of L- and D-Arg sequences were confirmed by flow cytometry, cytotoxicity assay, and analytical RP-HPLC with MALDI-TOF mass. All investigated LOAPs penetrated the cell efficiently with low cellular toxicity. The LOAPs having D-Arg residues at their N-termini seemed to have better metabolic stability than the LOAPs having C-terminal D-Arg residues. The metabolic degradation patterns were similar among all investigated LOAPs. The major hydrolytic site was between lauroyl group and β-Ala residue. Without the lipid chain, the oligoarginine peptide was pumped out ofcells easily. The results presented in this study suggest that structurally modified LOAPs could be used as a novel CPP design toward improved therapeutic application.

DOI10.1002/bip.21681
Alternate JournalBiopolymers
PubMed ID22252426
PubMed Central IDPMC3261498
Grant ListP50 CA126752-02 / CA / NCI NIH HHS / United States
R01 CA135312 / CA / NCI NIH HHS / United States
CA135312 / CA / NCI NIH HHS / United States
P50 CA126752 / CA / NCI NIH HHS / United States
CA126752 / CA / NCI NIH HHS / United States
R21 CA114149 / CA / NCI NIH HHS / United States
R33 CA114149 / CA / NCI NIH HHS / United States
R01 CA135312-03 / CA / NCI NIH HHS / United States
R33 CA114149-04 / CA / NCI NIH HHS / United States
CA114149 / CA / NCI NIH HHS / United States
Related Institute: 
Molecular Imaging Innovations Institute (MI3)

Weill Cornell Medicine
Department of Radiology
525 East 68th Street New York, NY 10065